June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Effect of the pre-treatment with the radioprotector ortho-phospho-L-tyrosine (pTyr) in a xenograft retinoblastoma mouse model
Author Affiliations & Notes
  • Alexander Viktor Tschulakow
    Division of Experimental Vitreoretinal Surgery, Center of Ophthalmology, Tuebingen, Germany
  • H. Peter Rodemann
    Division of Radiobiology & Molecular Environmental Research, Department of Radiation Oncology, University Hospital, Tuebingen, Germany
  • Stephan M. Huber
    Department of Radiation Oncology, University Hospital, Tuebingen, Germany
  • Monika Rittgarn
    Division of Experimental Vitreoretinal Surgery, Center of Ophthalmology, Tuebingen, Germany
  • Dominik Klumpp
    Department of Radiation Oncology, University Hospital, Tuebingen, Germany
  • Benjamin Steegen
    Department of Radiation Oncology, University Hospital, Tuebingen, Germany
  • Ulrich Schraermeyer
    Division of Experimental Vitreoretinal Surgery, Center of Ophthalmology, Tuebingen, Germany
  • Sylvie Julien-Schraermeyer
    Division of Experimental Vitreoretinal Surgery, Center of Ophthalmology, Tuebingen, Germany
  • Footnotes
    Commercial Relationships   Alexander Tschulakow, None; H. Peter Rodemann, None; Stephan Huber, None; Monika Rittgarn, None; Dominik Klumpp, None; Benjamin Steegen, None; Ulrich Schraermeyer, None; Sylvie Julien-Schraermeyer, None
  • Footnotes
    Support  Deutsche Kinder Krebs Stiftung (DKKS 2012.08).
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1775. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alexander Viktor Tschulakow, H. Peter Rodemann, Stephan M. Huber, Monika Rittgarn, Dominik Klumpp, Benjamin Steegen, Ulrich Schraermeyer, Sylvie Julien-Schraermeyer; Effect of the pre-treatment with the radioprotector ortho-phospho-L-tyrosine (pTyr) in a xenograft retinoblastoma mouse model. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1775.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinoblastoma (Rb) is the most frequent intraocular tumor in children and if left untreated, can cause death. Like most head and neck tumors, Rb is sensitive to radiotherapy (RT). However, the residual risk of a recurrence and development of treatment-induced secondary tumors still remains. In a previous study (Tschulakow et al., IOVS 2015; 56(7):72), we analyzed the ability of the radioprotector ortho-phospho-L-tyrosine (pTyr) to prevent radiation therapy-induced secondary tumors in Rb+/- mice, a model for Rb patients with hereditary Rb who are predisposed to secondary malignancies after RT. We showed that the pre-treatment with pTyr significantly reduces the negative effects of radiation on the hair coat as well as in the retina (retinal thickness reduction and photoreceptor loss) of Rb+/- mice. However, independent of the pre-treatment with pTyr, no secondary tumors were detectable.
In this study, we used a new xenograft Rb mouse model, which was developed by our group (Tschulakow et al., 2016), to investigate the tumor’s recurrence and the occurrence of secondary tumors after radiotherapy and possible ways of preventing them by the application of pTyr.

Methods : Immune-deficient nude mice carrying orthotopic human Y79 xenograft tumors were treated by RT (15 fractions of 5 Gy 6 MV photons during 3 weeks) with and without pre-treatment with pTyr. The animals were investigated in vivo using SLO/OCT and histologically 1, 3, 6 and 9 months after RT. Success of the RT as well as radiation-induced tumor development and normal tissue radiation toxicity were evaluated as a function of pTyr treatment.

Results : In the xenografted Rb model, tumor control was reached in 16 out of 22 control eyes after RT whereas it was not observed in all of the 24 pTyr-treated eyes. No secondary tumors were detected.

Conclusions : Although pTyr has a protective effect on normal tissues, unfortunately it dramatically lowers the efficacy of RT and is therefore not suitable for RT in Rb patients.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×